Document is current
Any future updates will be listed below
-
Authors
Doyle, Colm
Herka, Krzysztof
Flynn, Sean M.
Melidis, Larry
Dhir, Somdutta
Schoenfelder, Stefan
Tannahill, David
Balasubramanian, Shankar
-
Funding
Funding for this research was provided by:
Leverhulme Trust (ECF-2021-398)
UK Research and Innovation (MR/T016787/1)
Babraham Institute (BBS/E/B/000C0421)
Cancer Research UK (C9545/A19863)
Wellcome Trust (209441/Z/17/Z)
- License Information
-
More Information
Article History
Received: 7 November 2024
Accepted: 21 May 2025
First Online: 4 June 2025
Declarations
:
: Not applicable.
: Not applicable.
: S.B. is a founder and shareholder of Biomodal Ltd, Genome Therapeutics Ltd. and RNAvate Ltd. L.M. is a consultant for Genome Therapeutics Ltd. and RNAvate Ltd. S.S. is a co-founder and shareholder of Enhanc3D Genomics Ltd.
